Publication | Open Access

5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib

Medicinal ChemistryOncologyHealth SciencesMedicinePharmacological AgentPharmacotherapyAnti-cancer AgentSynergistic Anticancer ActivityPharmacologyRadiation OncologyPharmaceutical ChemistryDrug DiscoveryDrug Resistance